Comparison study for the best use of the biologic agent in rheumatoid arthritis treatment with certolizumab pegol in the real world

Comparison study for the best use of the biologic agent in rheumatoid arthritis treatment with certolizumab pegol in the real world - Beagle study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016340

Enrollment

Registered

2015-02-16

Start date

2015-02-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who treated with certolizumab pegol.

Exclusion criteria

Exclusion criteria: Subjects who are inadequate for the treatment with certolizumab pegol according to the attached document of the drug must be excluded from participation in this study.

Design outcomes

Primary

Measure	Time frame
The primary efficacy endpoint will be the percentage of subjects who achieve good response at 24W	—

Countries

Japan

Contacts

Public ContactHiroko Yamazaki

CAPITAL MEDICA CO,Ltd Clinical Trial Department

Hiroko.yamazaki@capimedi.com0355012271

Outcome results